NTLA Q3 2019 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+43.3% YoY

Gross Profit

-$17M-159.2% margin

Operating Income

-$25M-238.6% margin

Net Income

-$24M-222.6% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-4.5%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$27M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$347M

Total Liabilities

$71M

Stockholders' Equity

$276M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$7M	+43.3%
Gross Profit	-$17M	-$16M	-6.7%
Operating Income	-$25M	-$24M	-5.1%
Net Income	-$24M	-$23M	-4.1%